Immunoglobulin polypeptide fractions from products of domestic animals
AssigneeIogenetics, LLC
InventorsRobert D. Bremel, Jane Homan
Life of this patent
Estimating the term…
Abstract
The present invention provides a means to prepare a product from domestic animal milk, blood or eggs which comprises an array of T-cell exposed motifs similar in identity, distribution and concentration to those found in human immunoglobulin variable regions and to prepare and apply the product as an immune modulating agent for administration either as a nutritional supplement or as a pharmaceutical product.
Claims18
A protein product comprising an immunoglobulin polypeptide fraction derived from a milk product of a domestic animal, wherein said immunoglobulin polypeptide fraction comprises a frequency of representation of at least 60% of the T-cell exposed motifs found in a reference database of T-cell exposed motifs selected from the group consisting of T-cell exposed motifs found in human germline immunoglobulin variable region sequences, T-cell exposed motifs found in somatically mutated human immunoglobulin variable region sequences and T-cell exposed motifs found in immunoglobulin constant chains,
- wherein said reference database comprises at least 40,000 unique T-cell exposed motifs,
- wherein said immunoglobulin polypeptide fraction is formulated as a liquid and
- wherein said immunoglobulin polypeptide fraction further comprises greater than about 25% w/w immunoglobulin polypeptides, wherein w/w is the weight of the immunoglobulin polypeptides per the total weight of the fraction on a dry basis.
An oral formulation comprising an immunoglobulin polypeptide fraction derived from a domestic animal, wherein said immunoglobulin polypeptide fraction comprises a frequency of representation of at least 60% of the T-cell exposed motifs found in a reference database of T-cell exposed motifs selected from the group consisting of T-cell exposed motifs found in human germline immunoglobulin variable region sequences, T-cell exposed motifs found in somatically mutated human immunoglobulin variable region sequences and T-cell exposed motifs found in immunoglobulin constant chains, wherein said reference database comprises at least 40,000 unique T-cell exposed motifs,
- said immunoglobulin polypeptide fraction further comprising greater than about 25% w/w immunoglobulin polypeptides, wherein w/w is the weight of the immunoglobulin polypeptides per the total weight of the fraction on a dry basis, and
- wherein said oral formulation is selected from the group consisting of a powder, a liquid, a capsule and a gel.
Dependencies are inferred from the claim text.